Webinar: Four Billion Cells in Four Days: A Scalable 3D Bioprinting Success Story

Webinar | Four Billion Cells in Four Days: A Scalable 3D Bioprinting Success Story

Human induced pluripotent stem cells (hiPSCs) are pivotal in advancing tissue engineering, particularly for transplantation therapy and disease modeling. Conventional 2D cell culture methods face scalability challenges due to high cost, space and handling constraints. To overcome these issues, Stanford University (CA, USA), in collaboration with Sartorius (Göttingen, Germany), developed and optimized a robust, scalable process using serum- and xeno-free growth medium used for optimal expansion of hiPSC aggregates in a 1L scale automated stirred-tank bioreactor system. These pluripotent aggregates were differentiated into cardiac, vascular, cortical and intestinal organoids and compacted into cellular bioinks for 3D bioprinting. The 3D bioprinted tissues demonstrated high post-printing viability and potential for vascular and neuronal differentiation, highlighting a promising pathway for billion-cell-scale organ engineering. The team’s next objective is to scale up this process in a 10L bioreactor system to enhance cell yield further and improve process efficiency.

What You Will Learn:

Explore alternatives to using 2D flask cultures to generate required cell quantities
Understand how a Design of Experiment approach can enhance the efficiency of cell culture processes
Explore strategies to maintain hiPSC pluripotency at various bioreactor scales
Learn more about how bioprinting can increase the availability of organs

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Watch

Rukmini Ladi

Segment Technology Manager, Cell Therapy

Rukmini is a Segment Technology Manager at Sartorius, where she drives the segment vision and provides process expertise to support cell therapy developers in building end-to-end workflows using Sartorius’ comprehensive advanced therapy solutions. She leads strategic partnerships with industry leaders and academic partners, fostering collaboration to deliver innovative solutions that advance the field of cell therapy.
Rukmini holds a Master of Science in immune engineering from the University of Kansas (USA) and a Master of Science in pharmaceutical sciences: pharmaceutics from Butler University (IN, USA). She also earned a Bachelor of Pharmacy from Pune University (India).

With several years of experience as a bioprocess development engineer, she specializes in the development of immune and stem cell therapy processes.

Mark Skylar-Scott

Assistant Professor, Bioengineering, Stanford University
Betty Irene Moore Children’s Heart Center’s Basic Science and Engineering (BASE) Initiative

Mark received his BA in MEng in engineering at Cambridge University (UK) in 2007. Under the supervision of Professor Mehmet Fatih Yanik at MIT (MA, USA) from 2007-2012, Mark’s PhD in medical and electrical engineering involved the creation of new methods to use femtosecond lasers to print protein structures in 2D and 3D to direct neural and endothelial cell development. After his PhD, Mark had a brief foray into the startup world at Formlabs (MA, USA), where he developed and tested 3D printer resins for the Form 1 stereolithography printer. Mark performed his postdoctoral research from 2013-2020 with Jennifer Lewis at Harvard (MA, USA), where he developed new methods of manufacturing vascularized biological tissues, organoids, soft robotics and metals. Mark is now a member of Stanford’s BASE Initiative of the Children’s Heart Center where he aims to develop integrative strategies for billion- and trillion-cell bioprinting towards therapeutic scale and whole-organ biomanufacturing.